Brave New Psychiatry
(Schöne neue Psychiatrie)
volumes, soft cover, together 944 pages, 89 illustrations, 14,8
x 21 cm. Berlin: Peter Lehmann Publishing 1996. Published in
two volumes in the German language
| Vol. 2
information in German
of delivery & payment
A two-volume book, that reveals the risks of psychiatric drugs as
well as the risks of electroshocks ruthless and easy to understand.
With advices how to withdraw responsible.
The two-volume new publication addresses primary
to the treated persons and their relatives und enables them a
grounded and independent decision: taking psychiatric drugs in
spite of considerable risks for the healthor better not.
If already a damage is done, then the proof should be made easier,
that it was caused by the treatment. Workers in the psychosocial
system can use the book as manual and work of reference.
Antidepressants, lithium, neuroleptics, tranquilizers, psychostimulants
and carbamazepine are given to more and more human beingsespecially
to women, children and the elderlyin increasing doses and
in combinations that have effects not to calculate. Though a critical
knowledge about their dangers is more important than ever. This
is concerning the new types of tranquilizers, antidepressants
and neuroleptics, too.
A chapter by its own is dedicated to the potential of dependence
on these substances as well as to advices how to come down.
The author is a qualified educationalist and specialist-book-writer
and in the board of different associations, for example PSYCHEX
(Switzerland) and the German Bundesverband
of [ex-] users and survivors of psychiatry). Since January
1997 he is chair of the European
Network of (ex-) Users and Survivors of Psychiatry. For the
two books he made a thorough investigation of 2500 medical, psychological
and pharmacological books and articles. But no background knowledge
is necessary for the reading of his two books. "Brave New
Psychiatry" replaces his book of success "Der chemische
Chemical Gag), which was published 1986 and particularly re-published
1990 and 1993. More
about Peter Lehmann
Additional information to "Brave New
Tranquilizers (Lorazepam, Valium etc.),
lithium, antidepressants (Faverin, Prozac etc.), neuroleptics (Compazine, Haldol
etc.), carbamazepine (Tegretol etc.) and psychostimulants (Ritalin, Tradon etc.)
are used more and more in the psychiatric and medical system, especially in the
general medicine and the paediatrics. Since 1985 the trend steadily goes away
from tranquilizers and towards antidepressants and neuroleptics.
on average 70% of all psychiatric drugs are administered to women, with increasing
age in rising tendency. Every seventh psycho-pill is swallowed by children less
than twelve years old. 15% of all children and adolescents and 25% of all adults
are considered as mentally disturbed, so they are possible consumers. Nothing
points out that the situation outside of Germany is fundamentally different.
Normally the treated persons do not receive information about the probable, the
possible and the not-excludable risks. They do not know, that some substances
had to be withdrawn from the drug-market in the one countries, but are sold without
restriction in the other countries, for example penfluridol (brand names: Cyperon,
Flupidol, Longoperidol, Longoran, Micefal, Semap) as a possible carcinogen, remoxipride
(Roxiam) because of blood damage, and triazolam (brand names: Apo-Triazo, Dumozolam,
Halcion, Novidorm, Novodorm, Novo-Triolam, Nuctane, Nu-triazo, Rilamir, Somniton,
Songar, Triasan, Triazoral) in connection with amnesia and black-outs. If people
want to have full information on the risks, which are connected with the administration
of psychiatric drugs and electroshocks, they have to give serious thoughts to
their mechanisms and effects, especially when doctors' interests in full information
leave much to be desired.
»Brave New Psychiatry« consists of two volumes,
which are enclosed particularly.
Peter Lehmann: "Brave
New Psychiatry", Vol. 1: "Wie Chemie und Strom auf Geist und Psyche
wirken" (= "How chemistry and electricity work on mind and psyche")
400 pages, 35 illustrations, 15 x 21 cm, ISBN 3-925931-09-0 /
978-3-925931-09-3. Berlin: Peter Lehmann Publishing 1996. €
19.90 / Price
in CHF / Order-No. 120 / instantly deliverable / English
language order form for orders directly at Peter Lehmann Publishing
language order form
In the centre
of attention in this volume are the many and diverse risks and damages in the
psychic and mental system. Main topics are: drug-caused emotional impoverishment,
changing of the personality, depression, desperation, suicide, confusion, delirium
and psychotic states; disturbances of the senses, memory, concentration, sleep
and dreams; self-trials of doctors; animal experiments.
In a special chapter
Leonard Roy Frank, the US-American expert on damages of electroshocks, shows the
negative effects (especially loss of memory) of this disputed method.
an extensive register and 1102 sources from all over the world.
Lehmann: "Brave New Psychiatry", Vol. 2 "Wie Psychopharmaka den
Körper verändern" (= "How psychiatric drugs change the
544 pages, 54 illustrations, 15 x 21 cm, ISBN 3-925931-10-4
/ 978-3-925931-10-9. Berlin: Peter Lehmann Publishing 1996. Out
In the centre of attention here are the psychiatric drugs' short-term,
medium-term and long-term risks and damages, which find expression
in the muscle and autonomic system, for example aspartly
life-dangerousmuscle-cramps, movement-disorders, genetic
damages, harms to the liver, heart and sexual-organs.
by its own is dedicated to the potential of dependence on theses substances. Its
special status is caused by the fact, that their administratorswith the
exception of tranquilizersdeny their potential of dependence. They conceal
possible withdrawal-symptoms, rebound-phenomenons, supersensibility-reactions
of the receptors as well as possible irreversible drug damages and change the
definitions into symptoms-alteration: for example chronic anxiety after long-term
administration of antidepressants or tranquilizers, states of confusion after
withdrawal from lithium and chronic psychosis after administration of neuroleptics.
Prudent advices, how the risk of relapse can be reduced and how withdrawal-effects
can be mitigated, balance this volume.
With an extensive register, too, and
1677 sources from all over the world.